FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older Gallery

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

维梧资本简介 Gallery

维梧资本简介

Serán Bioscience Announces Investment by Vivo Capital Gallery

Serán Bioscience Announces Investment by Vivo Capital

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China Gallery

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

Vivo Capital Appoints New Managing Partners and Partners Gallery

Vivo Capital Appoints New Managing Partners and Partners

Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B Gallery

Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders Gallery

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders